Response to Tyrosine Kinase Inhibitors in Patients with BCR-ABL1 Positive Chronic Myeloid Leukemia; 20 Years’ Experience at Patan Hospital, Nepal
Chronic Myeloid Leukemia (CML) is characterized by the accumulation of immature white blood cells due to the Philadelphia chromosome, producing the BCR-ABL1 oncogene.Targeted therapies like Imatinib, Dasatinib, Nilotinib, and Ponatinib inhibit BCR-ABL1 activity, transforming CML into a manageable condition with favorable outcomes.
Authors
- Gyan Kayastha (ORCID: https://orcid.org/0000-0001-8043-9694)
- Pragya Rai (ORCID: https://orcid.org/0000-0003-0856-9050)
- Cellina Maharjan
- Nabina Thapa
Institutions
- Patan Academy of Health Sciences (NP)
Publication Details
- Journal
- International Journal of Cancer Care and Delivery
- Published
- 2024-10-06
- DOI
- https://doi.org/10.53876/001c.123900
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00